Kovack Advisors’s Novo Nordisk NVO Stock Holding History

Kovack Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$298K	Buy	6,144 +431	+8%	+$18.5K	0.01%	796
2026 Q1	$209K	Buy	5,713 +1,751	+44%	+$83K	0.01%	913
2025 Q4	$202K	Sell	3,962 -147	-4%	-$7.52K	0.01%	945
2025 Q3	$228K	Buy	+4,109	New	+$241K	0.02%	535
2025 Q1	–	Sell	-4,798	Closed	-$413K	–	617
2024 Q4	$413K	Sell	4,798 -1,225	-20%	-$132K	0.04%	357
2024 Q3	$717K	Sell	6,023 -392	-6%	-$52.3K	0.08%	225
2024 Q2	$916K	Buy	6,415 +106	+2%	+$14K	0.1%	177
2024 Q1	$810K	Buy	+6,309	New	+$751K	0.1%	173

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Kovack Advisors's NVO Position: Q2 2026 in Review

Kovack Advisors increased its Novo Nordisk (NVO) stake by 7.5% in Q2 2026, buying an estimated $18.5K and bringing the position to 6,144 shares worth $298K. The position accounts for 0.01% of the portfolio, ranked #796.

Kovack Advisors first reported a position in NVO in Q1 2024 and has held it in 8 quarters since. The position peaked at $916K in Q2 2024. 1,354 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Kovack Advisors held 6,144 shares of Novo Nordisk worth $298K as of Q2 2026.
Kovack Advisors bought 431 Novo Nordisk shares in Q2 2026, an estimated $18.5K.
Novo Nordisk made up 0.01% of Kovack Advisors's portfolio in Q2 2026, its #796 holding.
Kovack Advisors first reported a position in Novo Nordisk in Q1 2024 and has held it in 8 quarters since.
Kovack Advisors's Novo Nordisk position peaked at $916K in Q2 2024.
1,354 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.